Cencora (COR) Stock Still Looks Undervalued On Cash Flow And Earnings
Cencora’s share price has risen strongly over the past few years, and with the stock last closing at US$303.44, the company now screens as undervalued on both its intrinsic value estimate, using a Discounted Cash Flow (DCF) approach, and on market multiples. This leaves investors weighing how much upside is left after such a run.
- Cencora has returned 183.0% over the past 5 years, which puts today’s valuation in sharp focus after a period of substantial shareholder gains.
- Expectations that Cencora can keep converting its revenue into solid cash flows may support the current valuation, while any pressure on margins or reimbursement terms could quickly change how the stock is priced.
- Across Simply Wall St’s broader checks, Cencora scores highly on value, with 5 of 6 tests pointing to the shares trading below what the fundamentals suggest.
The issue now is whether Cencora’s current price already reflects most of that intrinsic value, or if the stock still offers a meaningful margin of safety.
Find out why Cencora's 3.6% return over the last year is lagging behind its peers.
Is Cencora Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model here is built on Cencora’s projected future free cash flows, adjusted back to today’s dollars. Based on this framework, the latest twelve month free cash flow sits at about $1.66b, with analysts and estimates assuming growing cash flows over time rather than a sharp decline or one off spike.
Rolling those projections together, the model points to an estimated intrinsic value of about $502 per share, compared with a recent share price of roughly $303. That gap implies Cencora trades at a 39.6% discount to the DCF estimate, even after the strong share price performance already logged in recent years.
On these cash flow assumptions, Cencora appears undervalued, with the DCF suggesting the share price is well below its estimated intrinsic value.
Our Discounted Cash Flow (DCF) analysis suggests Cencora is undervalued by 39.6%. Track this in your watchlist or portfolio, or discover 45 more high quality undervalued stocks.
Is Cencora Still Cheap on Earnings?
The P/E ratio is a useful cross check for Cencora because it ties the current share price directly to the earnings the business is already producing. At a P/E of about 23.2x, Cencora trades below the broader Healthcare sector average of roughly 24.9x and also below the peer group average of around 30.3x.
On Simply Wall St’s model, a fair P/E for Cencora, based on its sector, business profile and risk factors, sits closer to 27.0x. That suggests the current multiple is under this more tailored benchmark, even after the stock’s strong run in recent years. For investors comparing Cencora to other healthcare stocks, the current P/E points to a market valuation that does not fully match the level implied by the fair ratio.
On the P/E multiple alone, Cencora’s stock appears undervalued compared with both its fair ratio and typical Healthcare sector peers.
See what the numbers say about this price — find out in our valuation breakdown.
The Cencora Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Cencora pick up where this valuation puzzle leaves off by spelling out which combinations of growth, margins and earnings would need to occur for the stock to be worth materially more or less than today’s price. Each narrative treats Cencora’s implied fair value as a thesis about the business that can be revisited over time. Together, they are available on the company’s Community page.
Cencora’s community views split sharply between those who see long term upside from its specialty focus and digital build out, and those who think rising costs and margin pressure could cap returns.
Bull case: 13% undervalued
"Cencora's ongoing investment in digital infrastructure and advanced analytics positions the company to capitalize on the accelerating digitization of healthcare and regulatory requirements like the Drug Supply Chain Security Act..."
Read the full Bull Case to see why Cencora could be undervalued
Bear case: 5% overvalued
"While Cencora is embedding AI tools and broader digital capabilities across its highly automated distribution network, the ongoing cost and complexity of these investments could limit the benefit to operating margin if efficiency gains or service upsell do not keep pace with spending..."
Read the full Bear Case to see why Cencora could be overvalued
Do you think there's more to the story for Cencora? Head over to our Community to see what others are saying!
The Bottom Line
Cencora still screens as undervalued, with both the Discounted Cash Flow (DCF) intrinsic value estimate and the P/E based comparison pointing in the same direction. The broader valuation checks are also supportive, which reduces the chance that a single metric is skewing the picture. For you as an investor, the key question from here is whether Cencora can sustain the cash flow and margin profile that underpins those models, or whether reimbursement pressure and rising costs erode enough profitability to justify the current discount.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com